Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: A randomized controlled trial

Author(s): Gotoh-M, Kamihira-O, Kinukawa-T, Ono-Y, Ohshima-S, Origasa-H.

Source: BJU International {BJU-INT}, 2005, Vol/Iss/Pg. 96/4 (581-586), ISSN: 1464-4096.

Objectives: To compare the efficacy and safety of two (alpha)(1a)/ (alpha)(1d) adrenoceptor (AR) antagonists with different affinity for the (alpha)(1)AR subtypes, tamsulosin and naftopidil, in the treatment of benign prostatic hyperplasia (BPH).

Patients and Methods: Patients with BPH were randomized to receive either tamsulosin or naftopidil. The primary efficacy variables were the changes in the total International Prostate Symptom Score (IPSS), maximum flow rate on free uroflowmetry, and residual urine volume. The secondary efficacy variables were average flow rate, changes in the IPSS storage score, IPSS voiding score, and quality-of-life (QoL) Index score, from baseline to endpoint (12 weeks). Data on all randomized patients were included in the safety analyses for adverse effects and changes in blood pressure.
Results: Of the 185 patients enrolled data for 144 who were eligible for inclusion in the efficacy analysis were analysed (75 from the tamsulosin and 69 from the naftopidil group). There was no significant difference in any variable at baseline between the groups. There were satistically significant improvements for all primary and secondary variables in both groups, except for residual urine in the tamsulosin group. However, there was no significant intergroup difference in the improvement of any efficacy variable between the groups. The adverse effects were comparable, with no significant differences in systolic and diastolic blood pressure after treatment in both groups.

Conclusions: This study suggests that naftopidil is as effective and safe as tamsulosin. Both drugs were effective in improving storage and voiding symptoms. However, there was no difference in clinical efficacy or adverse effects between the (alpha) (1) AR antagonists with different affinity to (alpha)(1) subtypes, (alpha)(1a) and (alpha)(1d).

BJU International Vol. 581

eXTReMe Tracker